Please provide your email address to receive an email when new articles are posted on . Descartes-08 is an autologous mRNA cell therapy indicated for many autoimmune diseases. The FDA granted the ...
Intermittent intravenous methylprednisolone pulse (IVMP) and mycophenolate mofetil (MMF) led to a complete clinical response in 93% of patients with juvenile dermatomyositis (JDM), with manageable ...
IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 ...
GAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune ...
A team investigating the pediatric inflammatory disease juvenile dermatomyositis (JDM) has received a € 350,000 grant from the Prinses Beatrix Spierfonds (Dutch Neuromuscular Foundation) for the ...
Neil is KSBY's Senior Reporter and anchor of KSBY News Daybreak. He's one of your dedicated community reporters for the City of San Luis Obispo. Myositis is a debilitating disease that causes ...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell ...
We report the first case of glossal necrotizing myositis by group A beta-hemolytic Streptococcus in an 8-year-old girl on chronic nonsteroidal anti-inflammatory drugs, immunomodulators, and steroids ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results